ALZN · Alzamend Neuro Inc
United States · RS rating 47 · As of 2026-10-14
| Price | 1.35 USD |
|---|---|
| 1-day change | +0.0% |
| RS rating (overall / 1M / 3M / 12M) | 47 / 9 / 86 / 18 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 20 / 20 / 22 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -93.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +48.3% |
| Market cap (USD) | $4.3M |